Table 7 The combined synergizing effects of Smac-mimetic (or IAP inhibitor) agents against selected cancers and cell types

APG-1387

Liver

HepG2 and HCCLM3

TNF-α, TRAIL

[253]

APG-1387

Ovarian

SKOV3

TNF-α

[254]

AT-406

Osteosarcoma

AT-406, Xenograft

doxorubicin

[255]

AZ58

Bladder

UMUC-6, UMUC-12, and UMUC-18

gemcitabine, cisplatin

[256]

Birinapant

AML

MLL-ENL AML

emricasan

[257]

Birinapant

Breast

SUM190, SUM149

TRAIL

[69]

Birinapant

Head and Neck

UM-SCC-46 and -11B xenograft

radiation

[258]

Birinapant

Non-small cell Lung

LKB1- and KRAS-mutated

ralimetinib

[259]

Birinapant

Ovarian

CAOV3, OVCAR4, SKOV3, OVCAR8, OV90, 1A9

docetaxel

[260]

Birinapant

Ovarian

OCAR3, OVCAR8

carboplatin/ paclitaxel

[261]

BV6

AML

51% primary AML cells

cytarabine

[262]

BV6

Glioblastoma

–

temozolomide

[263]

BV6

CRC

SW480, HT-29, HCT-15

radiation

[264]

BV6

Glioblastoma

A172, T98G

temozolomide

[265]

BV6

Multiple

HT1080, HeLa, Jurkat, L363, MMI, OPM2, RPMI, HT29

TNF-α, TRAIL

[266]

BV6

Renal

CaKi1, KTCTL26, 786O, KTCTL30, KTCTL2

interferon-α

[267]

JP-1201

CRC

HT-29

radiation

[268]

JP-1201

Pancreas

Xenograft MIA PaCa-2

gemcitabine

[269]

LCL161

B-Cell Lymphoma

Xenograft Raji/4RH

rituximab, gemcitabine, vinorelbine

[270]

LCL161

Breast

MCF7-TamC3

tamoxifen

[271]

LCL 161

HNSCC

human cell culture, xenograft

radiation

[272]

LCL161

HNSCC

PCI-1, PCI-9, PCI-13, PCI-52, PCI-68

FAS-L

[273]

SM-164

Breast

(SK-BR3) and (MDA-MB-468

radiation

[274]

SM-164

Breast, Prostate, Colon

Cell lines

TRAIL

[275]

SM-164

Pancreatic

Panc-1, AsPC-1, BxPC-3

gemcitabine

[276]

compound A

Bladder

UC-9. UC-14, RT4 v1, RT4 v6

TRAIL

[277]

compound 3

Pancreas/CRC

Panc-1 and HCT116

doxorubicin

[278]

Debio 1143

Lung

LLC-OVA

radiotherapy

[279]

SH122

Prostate

DU145, CL1

TRAIL

[280]

SW IV-134

Pancreatic

PANC-1, CFPAC-1, BxPC-3, AsPC-1, MIA PaCa-2

gemcitabine

[281]